EUVIMEDEUVIMED entdecken
BeobachtungsstudieKohortenstudieOpen Access · CC BY-NC 4.0

A retrospective observational cohort study of oral azithromycin treatment for Legionnaires’ disease

Lorna Pairman iD, Yong Tai Beh, Hannah Maher, Sharon J Gardiner, Paul Chin, Jonathan Williman, Stephen T Chambers

Journal of Antimicrobial Chemotherapy · 2025

DOI: 10.1093/jac/dkaf081 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Lorna Pairman und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Otago Christchurch, 2 Riccarton Avenue, Christchurch, New Zealand. Hauptthemen laut MEDLINE: Azithromycin, Anti-Bacterial Agents, Legionnaires' Disease. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Legionnaires’ disease (LD) is typically treated with macrolides, including the azalide azithromycin, or quinolones. In 2013, guidelines for empirical treatment of community-acquired pneumonia at Christchurch Hospital, New Zealand were changed to prioritize oral azithromycin over IV clarithromycin.

Objectives

To determine whether the change in antimicrobial guidelines led to altered outcomes for patients subsequently confirmed to have LD.

Methods

Patients with confirmed LD between 2010 and 2020 were identified from clinical and laboratory data. Hospital records were used to identify mortality, ICU admission, length of hospital stay, time to clinical stability, and time to first anti-Legionella treatment. Mean differences, risk ratios (RRs) and an interrupted time series with propensity adjustment were used to compare patient outcomes before and after the guideline change.

Results

There were 323 patients included: 128 before and 195 after the change. Patient outcomes generally improved after the change including: mortality within 30 days (RR 0.4, 95% CI 0.2–0.8); ICU admission (RR 0.6, 95% CI 0.5–0.9); length of stay (difference −2.3 days, 95% CI −4.3 to −0.4); and time to clinical stability (difference −2.4 days, 95% CI −4.3 to −0.5). The interrupted time series analysis suggested improvements in patient outcomes may have occurred regardless of the guideline change.

Conclusions

Outcomes for patients with LD were not worsened by the change in antimicrobial guidelines and may have improved. Overall rates of mortality were low. This result was reassuring given the harm that may result from unnecessary use of IV compared with oral antimicrobial agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AzithromycinAnti-Bacterial AgentsLegionnaires' DiseaseHumansMaleFemaleAgedRetrospective StudiesAdministration, OralMiddle AgedNew ZealandLength of StayTreatment OutcomeAged, 80 and overCommunity-Acquired InfectionsClarithromycinPractice Guidelines as Topic

Substanzen

AzithromycinAnti-Bacterial AgentsClarithromycin

Autor:innen und Institutionen

  • Department of Medicine, University of Otago Christchurch, 2 Riccarton Avenue, Christchurch, New Zealand.
  • Department of General Medicine, Te Whatu Ora Health NZ-Waitaha Canterbury, Christchurch Hospital, 2 Riccarton Avenue, Christchurch, New Zealand.
  • Department of Medicine, Te Whatu Ora Health NZ-Hauora a Toi Bay of Plenty, Tauranga Hospital, 829 Cameron Road, Tauranga, New Zealand.
  • Department of Pathology and Biomedical Science, University of Otago Christchurch, 2 Riccarton Avenue, Christchurch, New Zealand.
  • Infection Management Service, Te Whatu Ora Health NZ-Waitaha Canterbury, Christchurch Hospital, 2 Riccarton Avenue, Christchurch, New Zealand.
  • Pharmacy Services, Te Whatu Ora Health NZ-Waitaha Canterbury, Christchurch Hospital, 2 Riccarton Avenue, Christchurch, New Zealand.

ORCID-Profile: Lorna Pairman

Zitieren

APA

Pairman, L., Beh, Y. T., Maher, H., Gardiner, S. J., Chin, P., Williman, J., & Chambers, S. T. (2025). A retrospective observational cohort study of oral azithromycin treatment for Legionnaires’ disease. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf081

Vancouver

Pairman L, Beh YT, Maher H, Gardiner SJ, Chin P, Williman J, et al. A retrospective observational cohort study of oral azithromycin treatment for Legionnaires’ disease. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkaf081

BibTeX
@article{Pairman2025,
  author = {Pairman, Lorna and Beh, Yong Tai and Maher, Hannah and Gardiner, Sharon J and Chin, Paul and Williman, Jonathan and Chambers, Stephen T},
  title = {A retrospective observational cohort study of oral azithromycin treatment for Legionnaires’ disease},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2025},
  doi = {10.1093/jac/dkaf081}
}
Kostenlos starten →